Search This Blog

Monday, August 21, 2023

Amgen's Lumakras facing FDA advisory panel for full approval

 The US FDA will hold an advisory committee meeting to discuss converting the accelerated approval of Amgen's (NASDAQ:AMGN Lumakras in non-small cell lung cancer.


Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)